In vitro susceptibility to ceftazidime/avibactam and comparators in clinical isolates of enterobacterales from five Latin American Countries

dc.contributor.authorAppel, Tobias Manuel
dc.contributor.authorMojica, María Fernanda
dc.contributor.authorde la Cadena, Elsa
dc.contributor.authorPallares, Christian José
dc.contributor.authorRádice, Marcela A.
dc.contributor.authorCastaneda-Mendez, Paulo
dc.contributor.authorJaime-Villalón, Diego A.
dc.contributor.authorGales, Ana
dc.contributor.authorMunita, Jose M.
dc.contributor.authorVillegas, María Virginia
dc.contributor.orcidMojica, María Fernanda [0000-0002-1380-9824]
dc.contributor.orcidde la Cadena, Elsa [0000-0003-0361-7893]
dc.contributor.orcidPallares, Christian José [0000-0002-6093-7845]
dc.contributor.orcidVillegas, María Virginia [0000-0003-1898-9067]
dc.date.accessioned2020-03-07T15:16:50Z
dc.date.available2020-03-07T15:16:50Z
dc.date.issued2020
dc.description.abstractenglishBackground: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which has shown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://dx.doi.org/10.3390/antibiotics9020062
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn2079-6382
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2011
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institutespa
dc.publisher.journalAntibioticsspa
dc.relation.ispartofseriesAntibiotics, 2079-6382, Vol. 9, Nro. 2, 2020spa
dc.relation.urihttps://www.mdpi.com/2079-6382/9/2/62/htm
dc.rightsAttribution 4.0 International*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf14
dc.rights.creativecommons2020
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.decsFarmacorresistencia microbianaspa
dc.subject.decsEnterobacter aerogenesspa
dc.subject.decsKlebsiella pneumoniaespa
dc.subject.keywordsAntimicrobial activityspa
dc.subject.keywordsArgentinaspa
dc.subject.keywordsColombiaspa
dc.titleIn vitro susceptibility to ceftazidime/avibactam and comparators in clinical isolates of enterobacterales from five Latin American Countriesspa
dc.title.translatedIn vitro susceptibility to ceftazidime/avibactam and comparators in clinical isolates of enterobacterales from five Latin American Countries
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Appel, T.M_2020.pdf
Tamaño:
223.68 KB
Formato:
Adobe Portable Document Format
Descripción:
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:

Colecciones